• Victory Capital Holdings, Inc. (NasdaqGS:VCTR) was recently added to several key S&P indices, including the S&P 1000, S&P 600, S&P 600 Financials, and S&P Composite 1500.
• This broad index inclusion has the potential to boost the company’s visibility among institutional investors and trigger increased demand through associated index funds.
• We’ll explore how this broad-based index inclusion could shape Victory Capital’s investment outlook and complement its ongoing business developments.

Outshine the giants: these 20 early-stage AI stocks could fund your retirement.

Victory Capital Holdings Investment Narrative Recap

To be a shareholder in Victory Capital Holdings, you need to believe in the company’s ability to deliver consistent earnings growth, realize synergies from acquisitions, and manage risks related to investment performance and business integration. Recent index inclusions, such as the S&P 1000 and S&P 600, could improve near-term visibility and attract new capital inflows, but they may not materially affect the key short-term catalyst, which remains the timely completion of the Amundi transaction. The biggest risk continues to be integration challenges with Amundi’s U.S. business, which could impact anticipated cost savings and margin improvement if not executed as planned.

Among recent developments, Victory Capital’s ongoing dividend increases stand out. The approval of a regular quarterly cash dividend of US$0.49 per share in May 2025 shows a continued commitment to returning capital to shareholders, which could complement the company’s enhanced profile following index inclusions by further appealing to income-focused investors. This may also reinforce confidence in sustained cash flow generation as Victory Capital works toward unlocking the benefits of its planned acquisition and expanded product offerings.

However, investors should be aware that, despite broader index exposure and improving returns, future profitability could still be impacted if the Amundi transaction faces...

Read the full narrative on Victory Capital Holdings (it's free!)

Victory Capital Holdings' narrative projects $1.8 billion revenue and $776.5 million earnings by 2028. This requires 25.5% yearly revenue growth and a $481.4 million earnings increase from $295.1 million currently.

Uncover how Victory Capital Holdings' forecasts yield a $70.96 fair value, in line with its current price.

Exploring Other Perspectives

You’ll find four unique fair value estimates from the Simply Wall St Community, ranging from US$50 to US$70.96 per share. As these predictions vary, remember that the timely integration of Amundi’s business remains a key focus for Victory Capital’s future performance, highlighting both opportunities and uncertainties for shareholders.

Explore 4 other fair value estimates on Victory Capital Holdings - why the stock might be worth as much as $70.96!

Build Your Own Victory Capital Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Victory Capital Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Victory Capital Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Victory Capital Holdings' overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 25 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 25 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com